Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Liposomal Amphotericin B · Fungizone

Small molecule · Acts on ergosterol · developed by Apothecon

Approved FDA, Oct 1965

2 Registered trials

What is Liposomal Amphotericin B?

Liposomal Amphotericin B (AmBisome) is a liposome-encapsulated polyene antifungal antibiotic that binds ergosterol in fungal cell membranes, disrupting membrane integrity and causing cell rupture. It also induces oxidative damage and stimulates host immune responses. The liposomal formulation increases drug concentration in target tissues while reducing systemic toxicity. It is studied in invasive aspergillosis and talaromycosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Fungizone, AmBisome
Drug type: Small molecule
Targets: ergosterol
Mechanism: Acts on ergosterol
Pathways: cell membrane integrity, oxidative damage
Therapy area: Infectious disease
Developer: Apothecon
In trials of: GILD, IQV
FDA status: Approved as Fungizone (October 13, 1965), NDA050313

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06525389	Phase 3	Talaromycosis	Not yet recruiting	GILD
NCT05101187	Phase 3	Invasive Aspergillosis	Active not recruiting	IQV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Invasive AspergillosisTalaromycosis

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z